Drug Profile
Lurbinectedin - PharmaMar
Alternative Names: JZP-712; Lurbinectedina - PharmaMar; LY-01017; PM-01183; PM-1183; Tryptamicidin; Zepsyre; ZEPZELCA; ZepzelcaLatest Information Update: 03 Apr 2024
Price :
$50
*
At a glance
- Originator PharmaMar
- Developer ADIUM PHARMA; Immedica; Jazz Pharmaceuticals plc; Luye Pharma Group; PharmaMar; Roche; Specialised Therapeutics Asia; Swiss Group for Clinical Cancer Research
- Class 3-ring heterocyclic compounds; Acetates; Alkaloids; Antineoplastics; Carbolines; Dioxolanes; Indoles; Small molecules; Spiro compounds; Tetrahydroisoquinolines
- Mechanism of Action Alkylating agents; DNA damage stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Small cell lung cancer
- Phase III Ovarian cancer
- Phase II/III Leiomyosarcoma
- Phase II Breast cancer; Malignant-mesothelioma; Non-small cell lung cancer; Pancreatic cancer; Sarcoma; Solid tumours
- Phase I/II Ewing's sarcoma; Soft tissue sarcoma
Most Recent Events
- 02 Apr 2024 Launched for Small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Macau (IV)
- 02 Apr 2024 Launched for Small cell lung cancer (Metastatic disease, Second-line therapy or greater, Late-stage disease) in Hong Kong (IV)
- 02 Apr 2024 Updated efficacy data from a phase I trial in small cell lung cancer released by Luye Pharma